Overview
Dengue is a mosquito-borne viral infection caused by any of four related dengue virus serotypes (DENV-1 through DENV-4). It is transmitted primarily by Aedes aegypti mosquitoes and is now endemic in more than 130 countries, making it the most widespread arthropod-borne viral disease globally.
According to the WHO, an estimated 400 million infections occur annually, of which approximately 100 million result in clinically apparent disease and 22,000 cause death. The 2024 global surge saw 14.6 million officially reported cases — a historic high — with epidemic transmission on every inhabited continent.
Global Burden (2024)
- 14.6 million reported cases
- >12,000 dengue-related deaths
- 130+ endemic countries
- 400 million estimated infections/year
Pathogen
- Family: Flaviviridae
- Genus: Orthoflavivirus
- 4 confirmed serotypes
- ssRNA+ genome, ~10.7 kb
Primary Vectors
- Aedes aegypti (primary)
- Aedes albopictus (secondary)
- Aedes polynesiensis (Pacific)
- Aedes scutellaris (Pacific)
Clinical Spectrum
- Undifferentiated fever
- Classic dengue fever
- Dengue with warning signs
- Severe dengue (DHF/DSS)
Full Taxonomic Classification
Dengue viruses are classified within the realm Riboviria and have undergone significant reclassification. The genus was renamed from Flavivirus to Orthoflavivirus by the International Committee on Taxonomy of Viruses (ICTV) in 2023.
The Four Serotypes
DENV-1
First isolated Hawaii 1944. Historically dominant worldwide. Genotypes I–V. GenBank reference: NC_001477 / KM204119
DENV-2
Prototype New Guinea C (1944). Most studied. 6 genotypes. Associated with severe disease in secondary infections. Reference: NC_001474 / KM204118
DENV-3
Prototype H87, Philippines 1956. Responsible for major 2019 outbreaks. 5 genotypes. Reference: NC_001475 / KU050695
DENV-4
Prototype H241, Philippines 1956. Least common globally. 4 genotypes. Reference: NC_002640 / KR011349
Serotype Independence: Infection with one serotype confers lifelong immunity to that serotype but only transient (~2–3 months) cross-protection. A subsequent infection with a different serotype greatly increases the risk of severe dengue (DHF/DSS) through antibody-dependent enhancement (ADE).
Genome and Genetic Data
Genome Architecture
The dengue virus genome is a single-stranded, positive-sense RNA molecule of approximately 10,697 nucleotides. It has a type I 5′ cap but lacks a 3′ poly-A tail. The genome encodes a single polyprotein of ~3,400 amino acids that is co- and post-translationally cleaved by viral and host proteases into 3 structural and 7 non-structural proteins.
Genome diagram. DENV genome map (~10.7 kb): structural proteins (red/orange — C, prM, E) and non-structural proteins NS1–NS5 (blue/teal/purple). NS5 encodes the RNA-dependent RNA polymerase — a primary drug target. Widths proportional to coding region length.
Protein Functions
| Protein | Type | Function | Drug Target? |
|---|---|---|---|
| C (Capsid) | Structural | Packages viral RNA genome | Research |
| prM/M (Membrane) | Structural | Chaperones E protein; cleaved on maturation | No |
| E (Envelope) | Structural | Cell attachment, fusion, major antigen; vaccine target | Vaccine |
| NS1 | Non-structural | RNA replication co-factor; diagnostic antigen | Research |
| NS2A | Non-structural | Membrane rearrangement, innate immune evasion | No |
| NS2B | Non-structural | NS3 protease cofactor | Research |
| NS3 | Non-structural | Serine protease + helicase; RNA replication | Active |
| NS4A | Non-structural | Membrane curvature, autophagy modulation | Research |
| NS4B | Non-structural | Replication complex scaffold; innate immune antagonism | Active (JNJ-A07, EYU-688) |
| NS5 | Non-structural | RNA-dependent RNA polymerase (RdRp) + methyltransferase; essential for replication | Active (AT-752) |
GenBank Reference Sequences
| Serotype | Prototype Strain | Origin | Year | NCBI Accession | Genome Size |
|---|---|---|---|---|---|
| DENV-1 | Hawaii | Hawaii, USA | 1944 | NC_001477 / KM204119 | 10,735 nt |
| DENV-2 | New Guinea C | Papua New Guinea | 1944 | NC_001474 / KM204118 | 10,723 nt |
| DENV-3 | H87 | Philippines | 1956 | NC_001475 / KU050695 | 10,707 nt |
| DENV-4 | H241 | Philippines | 1956 | NC_002640 / KR011349 | 10,649 nt |
All reference sequences available at NCBI Virus and NCBI GenBank. The WHO-FDA reference standards for nucleic acid testing were established using the KM204119/KM204118/KU050695/KR011349 series.
Genetic Diversity: Genotypes per Serotype
| Serotype | Number of Genotypes | Notes |
|---|---|---|
| DENV-1 | 5 (I–V) | Genotype I dominant in Asia–Pacific; Genotype V in Americas |
| DENV-2 | 6 | Asian/American genotype historically linked to DHF |
| DENV-3 | 5 (I–V) | Genotype III caused 2019 global surge |
| DENV-4 | 4 (I–IV) | Less characterized; least prevalent serotype globally |
Emerging Research — DENV-5: A putative fifth serotype was reported in 2013 from sylvatic (jungle) cycles in Malaysia (Mustafa et al., Nature). As of 2025, DENV-5 has not been formally confirmed by ICTV and remains under investigation. If confirmed, it would represent a significant challenge for existing tetravalent vaccines.
Vectors and Transmission
Dengue is transmitted through the bite of infected female Aedes mosquitoes. Unlike many other Aedes-transmitted arboviruses, dengue does not circulate among animal reservoirs in urban settings — humans are the primary amplifying host.
Aedes aegypti — Primary Vector
- Family: Culicidae
- Genus: Aedes
- Origin: Sub-Saharan Africa
- Highly urban-adapted; breeds in artificial containers
- Day-biting; peak activity at dawn and dusk
- Responsible for >90% of dengue transmission
- Intrinsic incubation period: 8–12 days
- Distribution: tropical/subtropical worldwide, <35°N/S latitude
Aedes albopictus — Secondary Vector
- Common name: Asian tiger mosquito
- Origin: Southeast Asia
- Invasive; now on all continents except Antarctica
- Cold-tolerant; reaches temperate regions
- Less efficient dengue vector than Ae. aegypti
- More important for chikungunya and Zika co-circulation
- Enables dengue transmission in Europe, North America
- Breeds in natural containers (tree holes) and urban sites
Aedes polynesiensis
- Region: Pacific Islands
- Competent vector for DENV-1, DENV-3
- Important in French Polynesia, Fiji, Tonga, Samoa
- Breeds in coconut shells, natural containers
Aedes scutellaris
- Region: Pacific Islands, Papua New Guinea
- Minor vector in sylvatic settings
- Competent for DENV-2 under experimental conditions
Transmission Routes
| Route | Frequency | Notes |
|---|---|---|
| Mosquito bite (vector-borne) | Primary (≥99%) | Female Aedes only; requires 8–12 day EIP |
| Vertical (mother to infant) | Rare | Perinatal dengue reported; can cause neonatal dengue |
| Blood transfusion / organ transplant | Very rare | Documented in traveler clusters; screening not routine globally |
| Needle-stick | Rare (laboratory) | Occupational exposure in research settings |
| Sexual transmission | Not documented | Unlike Zika; no credible evidence in dengue |
Climate Change Impact: Rising global temperatures and urbanization are expanding the geographic range of Ae. aegypti and Ae. albopictus. Models project dengue-endemic zones could expand to cover 60% of the global population by 2080, including parts of Europe and North America not currently at risk (ECDC, 2024).
Geographic Distribution
Dengue is endemic in more than 130 countries. The Americas experienced an unprecedented surge in 2024, reporting over 13 million cases — more than 80% of the global total. Below is a regional overview of endemic countries.
- Brazil (epidemic 2024)
- Colombia
- Peru
- Ecuador
- Bolivia
- Venezuela
- Paraguay
- Argentina
- Guyana
- Suriname
- French Guiana
- Chile (emerging)
- Mexico
- Guatemala
- Honduras
- El Salvador
- Nicaragua
- Costa Rica
- Panama
- Cuba
- Haiti
- Dominican Republic
- Puerto Rico (US)
- Jamaica
- Trinidad and Tobago
- India
- Indonesia
- Bangladesh
- Thailand
- Myanmar
- Vietnam
- Philippines
- Malaysia
- Sri Lanka
- Cambodia
- Laos
- Nepal
- Timor-Leste
- China (southern)
- Taiwan
- Singapore
- Fiji
- French Polynesia
- Papua New Guinea
- Samoa
- Vanuatu
- Solomon Islands
- Australia (QLD, imported)
- Nigeria
- Kenya
- Tanzania
- Mozambique
- Burkina Faso
- Sudan
- Yemen
- Saudi Arabia
- Pakistan
- Djibouti
- Somalia
- Cameroon
- Côte d'Ivoire
- France (incl. overseas territories)
- Italy (local transmission 2023–24)
- Spain (local transmission)
- Croatia (2010 outbreak)
- Portugal (Madeira 2012)
- Greece (sporadic)
- Ae. albopictus present in 28 EU countries
2024 Scale: The Pan American Health Organization (PAHO) confirmed the Americas broke all historical records in 2024, with Brazil alone reporting >6 million cases. The WHO declared a global emergency of international concern for dengue in several endemic regions.
Current Treatments and Contraindications
No Approved Antiviral: As of 2025, there is no specific antiviral drug approved for treatment of dengue. Management is entirely supportive and symptomatic. Early recognition of warning signs is critical to prevent dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).
Recommended / Supportive Treatments
Fever and Pain Management
RecommendedParacetamol (Acetaminophen) — First-line for fever and myalgia. Dose: 10–15 mg/kg every 6 hours (max 60 mg/kg/day). Note: A 2023 RCT raised concerns about transaminase elevation; close monitoring advisable.
Fluid Management
RecommendedOral rehydration for mild dengue. IV crystalloid fluids (normal saline, Ringer's lactate) for severe dengue with plasma leakage. Fluid resuscitation must be carefully titrated — both under- and over-hydration are dangerous.
Platelet Transfusion
Caution — Selective UseWHO guidelines do not recommend prophylactic platelet transfusion. Reserved for platelet count <10,000/µL with active bleeding or <20,000/µL with significant bleeding risk. Routine transfusion at <50,000/µL is not supported by evidence.
Dengue Vaccines (Prevention)
Approved (conditional)Dengvaxia® (CYD-TDV, Sanofi) — WHO-approved for seropositive individuals ≥9 years in endemic areas.
Qdenga® (TAK-003, Takeda) — WHO-recommended for children 6–16 years in high-burden endemic settings; two doses 3 months apart.
Shock Management
ICU ProtocolDengue shock syndrome requires immediate aggressive IV fluid resuscitation. Vasopressors may be required. Fresh frozen plasma or colloids for refractory shock. Intensive monitoring of hematocrit, urine output, and hemodynamics.
Monitoring Parameters
Standard CareSerial CBC (platelet count, hematocrit), liver enzymes (AST/ALT), fluid balance charts, vital signs q4–6h during critical phase (days 3–7). NS1 antigen and dengue IgM/IgG for diagnosis.
Contraindications and Drugs to Avoid
Aspirin (Acetylsalicylic Acid)
ContraindicatedInhibits platelet aggregation and prolongs bleeding time — extremely dangerous in dengue-associated thrombocytopenia. Increases risk of hemorrhage. Strictly avoid in all dengue patients.
NSAIDs (Ibuprofen, Naproxen, Diclofenac)
ContraindicatedAnti-platelet effects and GI mucosal damage risk combine with dengue-induced thrombocytopenia to create severe hemorrhagic risk. Avoid all NSAIDs throughout illness.
Corticosteroids
Not RecommendedControlled trials show no benefit and potential harm. Risks include GI bleeding, hyperglycemia, and immunosuppression. Exception: rare autoimmune complications (ITP, HLH) with specialist oversight.
Antibiotics
CautionDengue is viral — antibiotics provide no therapeutic benefit. May be appropriate only if concurrent bacterial co-infection is confirmed. Routine empirical antibiotics contribute to antimicrobial resistance.
Dengvaxia in Seronegative Individuals
ContraindicatedIn dengue-naïve individuals, Dengvaxia mimics a primary infection. Subsequent natural infection behaves as a secondary infection, dramatically increasing risk of severe dengue (ADE mechanism). Requires pre-vaccination serotesting.
Aggressive IV Fluid in Non-Shock Phase
CautionOver-hydration before plasma leakage phase can worsen respiratory compromise. Fluid strategy must be matched to clinical phase. Post-leakage phase (recovery days 7–10): risk of fluid overload.
WHO Clinical Phase Classification
| Phase | Timing | Key Features | Management Focus |
|---|---|---|---|
| Febrile | Days 1–3 | High fever, flush, myalgia, headache; positive tourniquet test | Symptom control; oral fluids; monitor for warning signs |
| Critical | Days 4–6 | Plasma leakage; thrombocytopenia; rising hematocrit; shock risk | Careful fluid balance; hospitalize; avoid fever temps return as "deceptive" |
| Recovery | Days 7–10 | Fluid reabsorption; bradycardia; possible fluid overload | Taper IV fluids; watch for pulmonary edema; mobilize |
Future Outlook and Pipeline
The dengue research pipeline is the most active it has ever been, driven by the 2024 epidemic surge. Multiple antiviral drug candidates are in clinical trials, novel vaccine platforms are advancing, and biological vector control has achieved landmark results.
Antiviral Drug Pipeline
AT-752 (Atea Pharmaceuticals) Phase I/II
Orally available guanosine nucleotide analog targeting the NS5 RNA-dependent RNA polymerase (RdRp). Active against all 4 serotypes in vitro. Phase II double-blind RCT ongoing in dengue patients in endemic settings.
JNJ-A07 (Janssen/J&J) Preclinical/Phase I
NS4B inhibitor that disrupts interaction between NS4B and NS3, blocking replication complex formation. Demonstrated pan-serotype activity against 21 clinical isolates. Potential first-in-class NS4B inhibitor.
EYU-688 (Novartis) Phase II
Small molecule targeting NS4B and somatostatin receptors. Dual-mechanism approach (direct antiviral + immunomodulatory). Phase II studies ongoing for dengue fever reduction.
V181 (Merck) — Vaccine Phase II/III
Quadrivalent purified inactivated virus (PIV) vaccine candidate. Not live-attenuated, avoiding the ADE concerns of Dengvaxia. May be safe for seronegative individuals — critical advantage.
mRNA Dengue Vaccines (Multiple developers) Phase I
Modelled on COVID-19 mRNA vaccine success. Candidates from Moderna and others target prM-E structural proteins. Offer flexibility for rapid serotype/strain updates. Scalable manufacturing.
Wolbachia-Infected Ae. aegypti (World Mosquito Program) Deployed
The most proven biological control strategy. Wolbachia (wMel strain) reduces dengue transmission by 77% (RCT, Yogyakarta, Indonesia, NEJM 2021). Deployed in 14 countries. Far North Queensland, Australia is now essentially dengue-free. WHO Vector Control Advisory Group endorsed this approach in 2020.
CRISPR Gene Drive (Research phase) Research
Gene drives could suppress or modify Ae. aegypti populations. Major ethical, ecological, and regulatory hurdles remain. Programs at NIH, Pirbright Institute, and University of California exploring self-limiting drives to prevent ecosystem disruption.
Niclosamide Nanoformulation Preclinical
Repurposed anthelmintic drug with broad antiviral activity. 2024 study in Nano Letters showed nanoengineered niclosamide can inhibit DENV replication at nanomolar concentrations. Oral bioavailability issues being addressed through nanoformulation.
Emerging Strategies
Sterile Insect Technique (SIT)
Mass-rearing of male Aedes mosquitoes sterilized by irradiation or Wolbachia infection. Releases reduce wild mosquito populations. Being piloted in conjunction with WHO in French Polynesia and Asia.
Broad-spectrum Flavivirus Antivirals
Pan-flavivirus antivirals could simultaneously treat dengue, Zika, and West Nile. NS5 methyltransferase and NS3 helicase are conserved across flaviviruses — ideal targets for broad-spectrum drugs.
AI/ML Drug Discovery
Machine learning models are accelerating identification of NS3 protease inhibitors and NS5 RdRp inhibitors by screening billions of compounds in silico. DNDi (Drugs for Neglected Diseases initiative) has partnered with computational drug discovery platforms for DENV.
Host-Directed Therapy
Targeting host factors required for DENV replication (e.g., clathrin-mediated endocytosis, lipid metabolism pathways). Less likely to drive viral resistance mutations. Multiple candidates in early-phase testing.
Postulated Path to Curing Dengue
No single intervention is likely to "cure" dengue in isolation. A complete solution requires an integrated, multi-pronged strategy attacking the problem at every level: the virus, the vector, the human immune response, and the socioeconomic drivers of transmission. Below is a scientifically grounded postulation.
Integrated Dengue Elimination Framework
Drawing from the WHO's Dengue Strategic Plan, PAHO recommendations, and current research, eliminating dengue as a public health threat would require simultaneous advances on six fronts:
Pan-serotype Antiviral Drug
A safe, orally bioavailable antiviral targeting a conserved viral protein (NS5 RdRp or NS3 helicase) active against all 4 (possibly 5) serotypes. AT-752 and EYU-688 represent current best candidates. Goal: reduce viremia, prevent severe disease progression.
Universal Dengue Vaccine
A safe, serostatus-independent tetravalent vaccine. The PIV approach (V181, Merck) or mRNA platforms may overcome the ADE problem of Dengvaxia. Target: ≥80% population coverage in endemic regions, providing herd immunity and interrupting transmission.
Biological Vector Elimination
Global scale-up of the Wolbachia method (World Mosquito Program) + Sterile Insect Technique. The Wolbachia approach reduces transmission by 77% without toxins. Combination with SIT and community-based larval source management provides a sustained reduction in vector populations.
Climate-Adaptive Surveillance
Real-time genomic surveillance (GISAID-style platform for DENV) to detect new serotypes, genotypes, and antiviral resistance early. AI-driven outbreak prediction models incorporating climate, population mobility, and vector data for pre-emptive responses.
WASH + Urban Planning
Eliminating Aedes breeding sites through clean water access, covered storage, improved solid waste management, and urban design that eliminates stagnant water habitats. Social determinants of health (poverty, crowding) are the root drivers of epidemic dengue.
Equitable Access
All tools must reach endemic low- and middle-income countries. International funding (GAVI, World Bank, PAHO), tiered pricing, and technology transfer agreements are non-negotiable prerequisites. A cure that only reaches wealthy nations will not eliminate the disease.
Scientific Assessment: With the convergence of mRNA vaccine technology, Wolbachia biocontrol success, and NS5/NS4B antiviral candidates entering Phase II/III trials, dengue elimination in high-burden regions within 15–20 years is scientifically plausible — but only with sustained political will, international funding, and community-centred implementation. The biological tools are converging. The gap is governance, equity, and deployment at scale.
Sources and References
All information drawn exclusively from government agencies, international health organizations, and peer-reviewed scientific literature. No blogs or commercial sites were used.
Government and Intergovernmental Organizations
- World Health Organization (WHO). Dengue and Severe Dengue — Fact Sheet. who.int
- WHO. Dengue Guidelines for Diagnosis, Treatment, Prevention and Control. TDR/WHO 2009 (updated). who.int
- WHO. Vaccines and Immunization: Dengue / Q&A on TAK-003. who.int
- U.S. Centers for Disease Control & Prevention (CDC). Clinical Care of Dengue. cdc.gov
- CDC. Areas with Risk of Dengue. cdc.gov
- CDC / EID. New Dengue Virus Lineages, Nicaragua, 2022. Vol. 30(6) 2024. wwwnc.cdc.gov
- PAHO/WHO. Regional Guidelines for Dengue Vaccine Safety Surveillance, QDENGA (TAK-003). paho.org
- European Centre for Disease Prevention & Control (ECDC). Dengue Worldwide Overview. ecdc.europa.eu
- NCBI / NIH. Dengue Virus — GenBank Reference Sequences. ncbi.nlm.nih.gov
- Australian DFAT Indo-Pacific Health Security. Wolbachia Method Deployment. dfat.gov.au
NGOs and Research Institutions
- World Mosquito Program (Monash University). Wolbachia Dramatically Reduces Dengue Cases. worldmosquitoprogram.org
- World Mosquito Program. Australia Progress — Dengue-Free Far North Queensland. worldmosquitoprogram.org
- DNDi (Drugs for Neglected Diseases initiative). Dengue antiviral research partnerships.
Peer-Reviewed Literature (NCBI/PMC)
- PMC. Dengue Virus Overview. PMC7149978. pmc.ncbi.nlm.nih.gov
- PMC. Dengue Viruses — An Overview. PMC3759171. pmc.ncbi.nlm.nih.gov
- PMC. Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines. PMC10111087. pmc.ncbi.nlm.nih.gov
- PMC. Management of Dengue: An Updated Review. PMC9793358. pmc.ncbi.nlm.nih.gov
- PMC. Current Trends and Limitations in Dengue Antiviral Research. PMC8544673. pmc.ncbi.nlm.nih.gov
- PMC. The Global Distribution of Aedes aegypti and Ae. albopictus. PMC4493616. pmc.ncbi.nlm.nih.gov
- PMC. Complete Genome Sequences DENV 1–4 (FDA/WHO Reference Reagents). PMC4751306. pmc.ncbi.nlm.nih.gov
- PMC. Wolbachia-Carrying Aedes Mosquitoes for Preventing Dengue Infection. PMC11005084. pmc.ncbi.nlm.nih.gov
- NCBI Bookshelf. Dengue Fever — StatPearls. NBK430732. ncbi.nlm.nih.gov